TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: passive glenohumeral range of motion in internal and external rotation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: scapular dyskinesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in HDRS-17 score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hop Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of stem cell compartments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinician Fidelity to TF-CBT Strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the number of pads used per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Positive predictive value of HD+ i-scan bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of net Clinical Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Children's PROMIS Pediatric Itch Short-Form
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean Change in PROMIS Pain Interference-Children (Adaptive Test)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response to lonafarnib
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cleveland Clinic Constipation Scoring System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: St. Mark's Fecal Incontinence Grading System
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mood profile
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregiving preparedness
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Caregiving outcomes
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Problem-solving ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reoperation as surrogate for recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Feasibility of Enrollment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility Retention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean change in pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With no Evidence of SARS-CoV-2 Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in augmentation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Results of 24 hour blood pressure monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Patients Experiencing a Grade 3 or Above Treatment-related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: change in severity of visual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacy staff competences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Return to Sports After Anterior Cruciate Ligament Injury Scale (ACL-RSI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Monitoring hypovolemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Arm Motor Fugl-Meyer Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of perineal tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: STI Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Vessel Wall MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success in Learning to Use a Videolaryngoscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Words in Noise Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Anti-Fxa Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Distance of the lateral midpoints of the nerve sheath contours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall health and well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Employee productivity measures (i.e., absenteeism and presenteeism)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: 2-year local control ratio of the treated liver area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: IgG4 Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgE Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Tissue Transglutaminase (tTG) IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Tissue Transglutaminase (tTG) IgA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-Deamidated Gliadin Peptide (DGP) IgG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prophylactic efficacy against P. falciparum infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Fluorescein Angiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optical Coherence Tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preliminary evidence of efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adhesion incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in muscle fiber cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Quadriceps Muscle Cross-Sectional Area (CSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Recovery time (duration of analgesia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of chosen immediate reward
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cross Sectional Area of Fat in Both Thighs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of the Girths in Both Thighs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants willing to be randomised
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Willingness of clinicians to allow participants to be recruited
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Follow up rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants who have their antibiotic therapy changed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS Subscale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occlusion of the stent or bypass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IFN-y Protein Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With Prevalence of Bone Metastases Without Progression
Endpoint domain: Mortality/survival
Primary endpoint: 2-year Recurrence Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Worst symptom score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Change From Baseline in Low Density Lipoprotein (LDL)-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sedation degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient's and endoscopist´s satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: propofol consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Score on the Connors Continuous Performance Test II (CCPT II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline C-MMSE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resolution of chylous fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of patients treated by each treatment alternative
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of pathological complete remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Brain Glycogen Turnover Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention at 8 Weeks
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Attendance at Intervention Classes
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Pain Outcomes Data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trauma team situational awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac iron overload
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mucosal Change in VCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Alveolar Size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With (Complete Response (CR) + Partial Response (PR))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of skin conductance fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to macular hole closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red blood cell (RBC) units transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in Patient-reported Adherence Medication Adherence Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes in low-density lipoprotein (LDL)-cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful removal of implant
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post-Operative Hip-Knee-Angle (HKA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-report drug craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective satiety response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Objective satiety response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total macular volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival Rate at 6 Months (PFS6)
Endpoint domain: Mortality/survival
Primary endpoint: All-cause in hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: AUC (Area under the curve) of SHR3824
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cmax (the maximum concentration) of SHR3824
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Qualitative detection of CMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety after administration of Varicella vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Physician Confidence in Dementia Care Skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Sense of Competence in Dementia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Dementia Attitudes Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Orbital Volume of the Injured Orbit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to resolution of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in 24-hour Weighted Mean Glucose (WMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported medical complications during flight
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Seated Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Seated Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evolution of clinical and electrophysiological pattern of neuropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pathologic Complete Response Rate (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Injury and Osteoarthritis Outcomes Scores (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants With HCV RNA Suppressed Below LLOQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in apnea hypopnea index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in hand washing behavior
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Proliferative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Shearwave stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed serum concentration (Cmax) of ABT-199
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax) of ABT-199
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant Stool Form Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Changes in Physical Activity Behavior
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of mania
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medication side effect profiles
Endpoint domain: Adverse events/effects
Primary endpoint: Breath gas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of Participants completing PDx and endorsing the exercise question
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of women treated as day care patients
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Proportion of patients with zoster pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: safety of combining Avonex with Zocor
Endpoint domain: Adverse events/effects
Primary endpoint: new or enlarging T2 lesions burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Recurrent hernia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reduction of overweight and obesity measured by sds-BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological diagnosis accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Severe and Life-threatening Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of EBUS-TBNA-RTE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in local and circulating compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported benefit
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent change in Best-Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomic changes in the macula as assessed with OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum level of HS-CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic Glycogen Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rates of Gluconeogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in Modified PedsQL GI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in self-rated symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assessed signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in UPDRS Part 2 and Part 3 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rCR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ORR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants Achieving HIV RNA <400 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Individual plasma concentrations of mycophenolic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hydroxyl radical measured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symmetry in External Work
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early detection of skin cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Ionized magnesium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Usability of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Engagement in advance care planning
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Presence of neutralizing AAV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Viability with treatment by protontherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bioanalytical measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: changes in carotid blood flow (measured by VTI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensorimotor rhythms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in Hemoglobin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients With Adverse Events and Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Determination of the Recommended Phase 2 Dose (RP2D) by Assessing Dose-limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate for injected tumor(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 28-Day Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Prevalence of resistance of specific mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of phenotypic resistance (fold change in susceptibility)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal dose of IRDye800CW-nimotuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Optimal time for IRDye800CW-nimotuzumab infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Tooth wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP-9 amount measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful nerve reconstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: diet behaviors (fruit and vegetable intake, sugary drink intake, and fast food intake)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes